Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.06.011Source: DataRank Database

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2021). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)OA: greenTopics (15)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Nicole Mittmann ORCID,Carolyn Owen ORCID,Nizar Abdel‐Samad,Graeme Fraser ORCID,Selay Lam

Live enrichment

PubMed:34334330 PMC:PMC8568662

National Institutes of Health

Grant: U10CA180821

National Institutes of Health

Grant: U10CA180882

National Institutes of Health

Grant: 704,970

National Institutes of Health

Grant: U10CA180863

National Institutes of Health

Grant: UG1CA233331

AbbVie

Pharmacyclics

Janssen Pharmaceuticals

National Cancer Institute

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8568662

publisherhttps://api.elsevier.com/content/article/PII:S2152265021002408?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265021002408?httpAccept=text/plain

MeSH Terms

HumansPiperidinesAdenineAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeSurvival AnalysisProspective StudiesAgedFemaleMaleLeukemia, Lymphocytic, Chronic, B-CellBendamustine HydrochlorideRituximab

Keywords

Economic analysisChronic Lymphocytic Leukemia, Ibrutinib, Bendamustine-rituximab, Phase Iii Trial

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

FAIR Checklist

Authors (20)

Funding (9 grants)

Open Access

Topics

Annotations (Europe PMC)